Area of research
Hematology · Molecular Biology
Research interest
Research interests include Acute Myeloid Leukemia Research, Multiple Myeloma Research and Treatments, Chronic Myeloid Leukemia Treatments, and Protein Degradation and Inhibitors.
Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AML
Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007
Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed <i>NPM1-</i>m or <i>KMT2A</i>-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory <i>NPM1</i>-m or <i>KMT2A</i>-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
PDE5 inhibition rescues mitochondrial dysfunction and angiogenic responses induced by Akt3 inhibition by promotion of PRC expression
Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved β <sub>2</sub> -Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury
5‐HT<sub>1F</sub> receptor‐mediated mitochondrial biogenesis for the treatment of Parkinson's disease